More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$6.12B
EPS
-15.46
P/E ratio
--
Price to sales
9.04
Dividend yield
--
Beta
0.758556
Previous close
$93.54
Today's open
$93.14
Day's range
$91.18 - $95.68
52 week range
$63.23 - $130
show more
CEO
Christopher Peetz
Employees
433
Headquarters
Foster City, CA
Exchange
NASDAQ Global Market
Shares outstanding
65282044
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing.
Business Wire • Nov 5, 2026

Mirum Pharmaceuticals Q3 Earnings Call Highlights
Mirum Pharmaceuticals NASDAQ: MIRM reported third-quarter net product sales of $186 million and raised its full-year 2026 net product sales guidance to $715 million to $720 million, citing continued growth of LIVMARLI and its bile acid medicines as well as progress across its late-stage pipeline.
MarketBeat • Nov 4, 2026

Mirum Pharmaceuticals, Inc. (MIRM) Q3 2026 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. ( MIRM ) Q3 2026 Earnings Call November 3, 2026 4:30 PM EST Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations Christopher Peetz - CEO & Director Peter Radovich - COO & President Rob Myers - Chief Medical Officer Eric Bjerkholt - Chief Financial Officer Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Luke Herrmann - Robert W. Baird & Co. Incorporated, Research Division Yesha Patel - Evercore ISI Institutional Equities, Research Division Kalpit Patel - Wolfe Research, LLC Ryan Deschner - Raymond James & Associates, Inc., Research Division James Condulis - Stifel, Nicolaus & Company, Incorporated, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Michael Ulz - Morgan Stanley, Research Division Lisa Walter - RBC Capital Markets, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Charles Wallace - H.C.
Seeking Alpha • Nov 4, 2026

Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update.
Business Wire • Nov 3, 2026

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to earnings of $0.05 per share a year ago.
Zacks Investment Research • Nov 3, 2026

Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q3 Earnings
While the top- and bottom-line numbers for Mirum Pharmaceuticals (MIRM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks Investment Research • Nov 3, 2026

Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver Meeting® 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver Meeting® 2026.
Business Wire • Nov 2, 2026

Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026.
Business Wire • Oct 27, 2026

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Oct 27, 2026

Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Patients Aged 6 to
Business Wire • Oct 26, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Mirum Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.